全球睡眠障礙市場分析：2009年至2024年 是由出版商Visiongain在2009年06月所出版的。
這份英文市場調查報告書包含153 pages 價格從美金2331起跳。
Abstract
Sleep disorders affect hundreds of millions of people worldwide. It is a
multi-billion dollar market for drug-based treatments with continuing
potential for growth. This new report - World Sleep Disorders Market Analysis
2009-2024 - explains the commercial prospects for drugs to treat sleep
disorders, an important, changing pharma market. The principal disorders are
insomnia, narcolepsy, sleep apnea and restless leg syndrome, but there are
other potentially profitable market segments. Overall, sleep disorders are
highly prevalent. Approximately 30% of the population worldwide suffer from
sleep disorders analysis suggests. Capturing a segment of this market has
enormous potential.
Total drug revenues in the sleep disorders market exceeded $7bn in 2008.
Visiongain expects the market to expand during the forecast period 2009-2024 -
but by how much? In this new study, you will discover market reach, both
worldwide and in major national markets, with leading products and submarkets
covered. Growth in the worldwide market will be driven by an increase in the
use of insomnia-alleviating and wake-promoting drugs in particular. The
treatment of insomnia and some other disorders will change during the forecast
period - this report tells you how. An extensive pipeline with new treatment
approaches - some close-to-market - will stimulate and increase profitablility
in this market sector. A shift from traditional treatments to new drugs will
improve treatment options, as well as broadening access to treatments,
including use of generic substitutes. New drugs should provide more-attractive
treatment options for patients and prescribers who have been deterred by the
limitations of existing treatments.
Under-diagnosed and under-treated, sleep disorders present a significant
market opportunity for existing and still-to-be-launched treatments.
Currently, there is large untapped market potential in the sleep disorder
market worldwide. Prescription drugs must compete with OTC products, natural
remedies and other treatments, however. Under-treatment is widespread, with
many sufferers not seeking medical guidance; that situation should gradually
improve, increasing commercial opportunities. The full commercial potential of
sleep disorder treatments has thus still to be achieved. The momentum in that
sector will increase as companies further invest there, along with healthcare
payers worldwide. This new report - Sleep Disorders Market Analysis 2009-2024
- is essential reading for anyone interested in the sleep disorders market.
There, you will discover prospects for both existing competitors and potential
market entrants from 2009 onwards.
Comprehensive analysis of the sleep disorders market area
Sleep Disorders Market Analysis 2009-2024 examines that market area
critically, through a comprehensive review of information sources, both
primary and secondary. This report provides detailed sales forecasts,
discussions of pipeline developments and analysis of commercial drivers and
restraints, including a SWOT analysis. There are many tables and figures
included. The result is a comprehensive market- and industry-centred report
with detailed analyses and informed opinion to benefit your work.
Why you should buy Sleep Disorders Market Analysis 2009-2024
Benefits from purchasing this report include:
- Your receiving a comprehensive analysis of the prospects for sleep
disorder treatments from 2009-2024, including predicted revenues, growth rates
and other important data.
- Your accessing forecasts for the top-selling drugs in all the prominent
sleep disorder markets, including detailed explanations of factors affecting
individual drug sales.
- Your receiving sales forecasts for leading sleep disorder country markets
worldwide
- Your identifying key pipeline developments, promising treatment avenues
and emerging drug targets.
- Your receiving expert views from our original survey
- Your discovering the important drivers and restraints in the market, and
how these operate worldwide
- Your finding out where the market is heading overall - both
technologically and commercially - from the present onwards.
There is great untapped potential in the sleep disorder market. Safety and
efficacy concerns still limit the commercial potential of sleep disorder
drugs, despite the vast potential treatment population - one of the largest in
medicine. Some market leaders will soon reach patent expiry. What effects will
generic competition have in the market? Will more-effective treatments emerge
soon, with commercial gains for innovators? What effects will OTC switching
have? This report covers those important questions and many others.
Table of Contents
1. Executive Summary: Sleep Disorders Market Analysis 2009-2024
2. An Introduction to Sleep Disorders
- 2.1 Sleep Hygiene
- 2.2 Measuring Sleep
- 2.3 Circadian Rhythm
- 2.4 Sleep Disorders
- 2.4.1 Dyssomnias
- 2.4.2 Parasomnias
- 2.5 The Treatment of Sleep Disorders
- 2.5.1 Therapeutic Approaches
- 2.5.2 Medical Therapies
- 2.5.3 Alternative Therapies
- 2.5.4 OTC Products
- 2.6 Pharmacological Treatments
- 2.6.1 Specific Treatments
- 2.6.2 Off-Label Treatments
3. The Global Sleep Disorder Market Forecast
- 3.1 The World Market
- 3.1.1 Growth in the World Sleep Disorder Market to 2012
- 3.1.2 Growth in the World Sleep Disorder Market from 2013
- 3.2 The Global Sleep Disorder Market Geographical Breakdown
- 3.2.1 Sleep Disorder Market Forecast - US
- 3.2.2 Sleep Disorder Market Forecast - Japan
- 3.2.3 Sleep Disorder Market Forecast - European Markets
- 3.2.4 Sleep Disorder Market Forecast - Emerging Markets
4. Insomnia Market Analysis and Forecasts
- 4.1 The Total Insomnia Market Forecast
- 4.1.1 Increased Use and Access to Insomnia Treatments Will Drive Market
Growth
- 4.1.2 Pipeline Treatments Will Revive the Insomnia Market
- 4.2 Ambien Forecast 2009-2024
- 4.2.1 How Will Generic Competition Impact Upon Ambien Sales?
- 4.2.2 Will Pipeline Products Make Ambien Treatment Obsolete?
- 4.3 Lunesta Forecast 2009-2024
- 4.3.1 Lunesta Will Experience Revenue Growth in the Early Forecast Years
- 4.3.2 Patent Expiry in 2012 - What Effects?
- 4.4 Lendormin Forecast 2009-2024
- 4.4.1 Lendormin Revenues Over the Forecast Period
- 4.5 Imovane Forecast 2009-2024
- 4.5.1 How Will Generics and Novel Compounds Affect Imovane Revenues?
- 4.6 Rozerem Forecast 2009-2024
- 4.6.1 Will Generic Eszopiclone Seriously Affect Rozerem Sales?
- 4.6.2 Generic Ramelteon and New Long-Term Treatment Options
- 4.7 Total Other Insomnia Drugs Market Forecast 2009-2024
- 4.7.1 Generic Zolpidem - What Effects on Market?
- 4.7.2 New Pipeline Agents and the Market Entry of More Generic Agents
- 4.7.3 Generic Ambien CR and Pipeline Products
- 4.8 Insomnia Market Summary
5. Restless Leg Syndrome Market Analysis and Forecasts
- 5.1 The Total RLS Market Forecast 2009-2024
- 5.2 Mirapex Forecast 2009-2024
- 5.2.1 Patent Expiries and Generic Competition
- 5.3 Requip Forecast 2009-2024
- 5.3.1 Competition from Generics and Pipeline Products
- 5.4 Total Other RLS Drugs Forecast 2009-2024
- 5.5 RLS Market Forecast Summary
6. Wake-Promoting Drugs Market Analysis and Forecasts
- 6.1 The Total Wake-Promoting Market Forecast 2009-2024
- 6.2 Provigil Forecast 2009-2024
- 6.2.1 How Will Sales of Provigil be Affected by Market Entry of Nuvigil?
- 6.2.2 Loss of Marketing Exclusivity from 2015
- 6.2.3 How Competition with Pipeline Agents Will Affect Growth to 2024
- 6.3 Nuvigil Forecast 2010-2024
- 6.3.1 Nuvigil Will Experience Consistent Growth from a Large Treatment
Base
- 6.3.2 Growth of Nuvigil Will Slow Due to Entry of New Agents
- 6.4 Xyrem Forecast 2009-2024
- 6.4.1 Xyrem Will See Increased Revenues in the Early Forecast Years
- 6.4.2 New Agents Will Result in Negative Growth in the Later Forecast
Years
- 6.5 Other Wake-Promoting Drugs: Forecast 2009-2024
7. Sleep Disorder Treatments: SWOT Analysis, 2009-2024
- 7.1 Market Drivers
- 7.2 Market Restraints
- 7.3 Current Treatments
- 7.4 The Large, Competitive Market
- 7.5 New Insomnia Drugs Will Drive Market Growth
- 7.6 High Sleep Disorder Prevalence and Unmet Market Needs
- 7.7 Public Opinion
- 7.8 Sleep Apnea Market Drivers and Restraints
8. The Sleep Disorder Treatment Pipeline
- 8.1 Insomnia Treatment Pipeline
- 8.1.1 Zolpimist (Novadel)
- 8.1.2 Edluar (Meda)
- 8.1.3 Silenor (Somaxon)
- 8.1.4 Indiplon (Neurocrine Biosciences)
- 8.1.5 Ciltyri (Sanofi-Aventis)
- 8.1.6 Intermezzo (Transcept)
- 8.1.7 Almorexant (GSK/Actelion)
- 8.1.8 Tasimelteon (Vanda)
- 8.1.9 Medodorm (Essential Nutrition)
- 8.1.10 Esmirtazapine (Schering-Plough)
- 8.1.11 Gabitril (Cephalon)
- 8.1.12 649868 (GSK)
- 8.1.13 EVT 201 (Evotec)
- 8.1.14 PD 200390 (Pfizer)
- 8.1.15 TIK 301 (Tikvah Therapeutics)
- 8.1.16 HY 10275 (Hypnion)
- 8.1.17 LY 2624803 (Eli Lilly)
- 8.1.18 Pruvanserin (Eli Lilly)
- 8.1.19 MK 4305 (Merck & Co)
- 8.1.20 TGARO1H (Fabre Kramer)
- 8.1.21 ITI 007 (Intra-Cellular Therapies)
- 8.1.22 Staccato Zaleplon (Alexza)
- 8.1.23 SKP 1041 (Somnus)
- 8.1.24 Pimavanserin (Acadia)
- 8.1.25 NBI 75043 (Neurocrine Biosciences)
- 8.1.26 Adipiplon (Neurogen)
- 8.1.27 Summary of Promising Late-Stage Insomnia Pipeline Products
- 8.2 Wake-Promoting Sleep Disorder Treatment Pipeline
- 8.2.1 Nuvigil (Cephalon)
- 8.2.2 Tiprolisant (Bioprojet)
- 8.2.3 CX 717 (Cortex)
- 8.2.4 VSF 173 (Vanda)
- 8.2.5 APD 916 (Arena)
- 8.2.6 COL 204 (CoLucid)
- 8.2.7 Concluding Thoughts on the Wake-Promoting Pipeline
- 8.3 Restless Legs Syndrome Treatment Pipeline
- 8.3.1 NEUPRO (UCB Pharma)
- 8.3.2 NENAD (Axxonis Pharma AG)
- 8.3.3 Solzira (Xenoport)
- 8.3.4 Aplindore (Neurogen)
- 8.3.5 JZP 7 (Jazz Pharmaceuticals)
- 8.3.6 Istradefylline (Kyowa Hakko Kirin)
- 8.3.7 Safinamide (Merck Serono)
- 8.3.8 Nitisinone (Synosia Therapeutics)
- 8.3.9 Concluding Notes on the RLS Pipeline
- 8.4 Sleep Apnea Pharmaceutical Treatment Pipeline
- 8.4.1 BGC20 0166 (BTG and Collegium)
- 8.4.2 AVE 0657 (Sanofi-Aventis)
- 8.4.3 CX 1739 (Cortex)
- 8.4.4 Gall 200 (Galleon)
- 8.4.5 Factors Affecting Sleep Apnea Pharmaceutical Market Potential
9. An Expert' s Opinion - Dr. Remy Luthringer
- 9.1 Unmet Needs in the Treatment of Sleep Disorders
- 9.2 The Future of the Wake-Promoting Market
- 9.3 The Insomnia Market
- 9.4 Long-Term and Off-Label Use of Insomnia Treatments
- 9.5 The Sleep Disorder Pipeline
- 9.6 The Evolution of Sleep Disorder Treatments
- 9.7 Growth in the Sleep Disorder Market
10. Conclusions
- 10.1 Sleep Disorders Constitute a Large Market Opportunity
- 10.2 The World Market for Sleep Disorder Treatments Will Grow Over the
Forecast Period
- 10.3 The Global Market Distribution Will Change over the Forecast Period
- 10.4 The Insomnia Treatment Market
- 10.5 Restless Leg Syndrome Treatment Market
- 10.6 The Wake-Promoting Drug Market
- 10.7 Drivers and Restraints
- 10.8 The Sleep Disorder Treatment Pipeline Overview
- 10.8.1 Insomnia Pipeline
- 10.8.2 Wake-Promoting Pipeline
- 10.8.3 Restless Legs Syndrome Pipeline
- 10.8.4 Sleep Apnea Pipeline
List of Tables
- Table 2.1 Dyssomnia Sleep Disorders
- Table 2.2 Parasomnia Sleep Disorders
- Table 3.1 Global Sleep Disorder Market Forecast Sales ($m), Growth (%) and
CAGR (%), 2009-2024
- Table 3.2 Sleep Disorder Comparative Forecast Sales ($m), 2009-2024
- Table 3.3 Sleep Disorder Comparative Forecast by Market Share (%),
2009-2024
- Table 3.4 Geographical Market Share (%) Forecast to 2024
- Table 3.5 Geographical Sales ($m) Forecast to 2024
- Table 4.1 Total Insomnia Market Forecast Sales ($m), Growth (%) and CAGR
(%), 2009-2024
- Table 4.2 Ambien Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 4.3 Lunesta Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 4.4 Lendormin Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 4.5 Imovane Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 4.6 Rozerem Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 4.7 Total Other Insomnia Drugs Forecast Sales ($m), Growth (%) and
CAGR (%), 2009-2024
- Table 4.8 Insomnia Drug Market Share (%) Comparative Forecast, 2009-2024
- Table 5.1 Total RLS Market Forecast Sales ($m), Growth (%) and CAGR (%),
2009-2024
- Table 5.2 Mirapex Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 5.3 Requip Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 5.4 Total Other RLS Drugs Forecast Sales ($m), Growth (%) and CAGR
(%), 2009-2024
- Table 5.5 RLS Drug Market Share (%) Comparative Forecast, 2009-2024
- Table 6.1 Total Wake-Promoting Market Forecast Sales ($m), Growth (%) and
CAGR (%), 2009-2024
- Table 6.2 Provigil Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 6.3 Nuvigil Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 6.4 Xyrem Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024
- Table 6.5 Total Other Wake-Promoting Drugs Forecast Sales ($m), Growth (%)
and CAGR (%), 2009-2024
- Table 7.1 A SWOT Analysis of the Sleep Disorder Market, 2009-2024
- Table 8.1 The Insomnia Treatment Pipeline, 2009
- Table 8.2 The Wake-Promoting Sleep Disorder Treatment Pipeline, 2009
- Table 8.3 The RLS Treatment Pipeline, 2009
- Table 8.4 The Sleep Apnea Pharmaceutical Treatment Pipeline, 2009
List of Figures
- Figure 3.1 Global Sleep Disorder Market Sales ($m), 2009-2024
- Figure 3.2 Sleep Disorder Comparative Forecast in Sales ($m), 2009-2024
- Figure 3.3 Sleep Disorder Comparative Forecast by Market Share (%),
2009-2024
- Figure 3.4 Global Market Share (%) Comparison, 2008
- Figure 3.5 Global Market Share (%) Comparison, 2024
- Figure 3.6 US Sleep Disorder Market Sales ($m) to 2024
- Figure 3.7 Japan Sleep Disorder Market Sales ($m) to 2024
- Figure 3.8 Europe Sleep Disorder Market Sales ($m) to 2024
- Figure 3.9 Emerging Markets Sleep Disorder Market Sales ($m) to 2024
- Figure 4.1 Total Insomnia Market Sales ($m), 2009-2024
- Figure 4.2 Ambien Sales ($m), 2009-2024
- Figure 4.3 Lunesta Sales ($m), 2009-2024
- Figure 4.4 Lendormin Sales ($m), 2009-2024
- Figure 4.5 Imovane Sales ($m), 2009-2024
- Figure 4.6 Rozerem Sales ($m), 2009-2024
- Figure 4.7 Total Other Insomnia Drugs Sales ($m), 2009-2024
- Figure 4.8 Comparative Insomnia Forecast in Sales ($m), 2009-2024
- Figure 4.9 Comparative Insomnia Forecast by Market Share (%), 2009-2024
- Figure 5.1 Total RLS Market Sales ($m), 2009-2024
- Figure 5.2 Mirapex Sales ($m), 2009-2024
- Figure 5.3 Requip Sales ($m), 2009-2024
- Figure 5.4 Total Other RLS Drugs Sales ($m), 2009-2024
- Figure 5.5 Comparative RLS Forecast in Sales ($m), 2009-2024
- Figure 5.6 Comparative RLS Forecast by Market Share (%), 2009-2024
- Figure 6.1 Total Wake-Promoting Market Sales ($m), 2009-2024
- Figure 6.2 Provigil Sales ($m), 2009-2024
- Figure 6.3 Nuvigil Sales ($m), 2009-2024
- Figure 6.4 Xyrem Sales ($m), 2009-2024
- Figure 6.5 Total Other Wake-Promoting Drugs Sales ($m), 2015-2024
- Figure 10.1 Global Sleep Disorder Market Sales ($m), 2009-2024
- Figure 10.2 Sleep Disorder Comparative Forecast Sales ($m), 2009-2024
- Figure 10.3 Total Insomnia Market Sales ($m), 2009-2024
- Figure 10.4 Total RLS Market Sales ($m), 2009-2024
- Figure 10.5 Total Wake-Promoting Market Sales ($m), 2009-2024
Companies Listed
- Acadia
- Actavis
- Actelion
- Alexza
- Apotex
- Arena
- Astellas
- Axxonis Pharma AG
- Barr
- Bayer
- Bioprojet
- Boehringer Ingelheim
- BTG
- Cephalon
- Collegium
- CoLucid
- Cortex
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Essential Nutrition
- Evotec
- Fabre Kramer
- Forenap Pharma
- Galleon
- GlaxoSmithKline
- Hypnion
- Intra-Cellular Therapies
- Italfarmaco
- Jazz Pharmaceuticals
- Kyowa Hakko Kirin
- Meda
- Merck & Co
- Merck Serono
- Mylan
- Neurocrine Biosciences
- Neurogen
- Novadel
- Orexo
- Pfizer
- Pharmascience
- Ranbaxy
- Sanofi-Aventis
- Schering-Plough
- Sepracor
- SkyePharma
- Somaxon
- Somnus
- Strada
- Synosia Therapeutics
- Takeda
- Teva
- Tikvah Therapeutics
- Transcept
- UCB Pharma
- Valeant
- Vanda
- Watson
- Wyeth
- Xenoport
|
